Drug
Onartuzumab clinical trials
Also written MetMAb and RO5490258.
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2012 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Bevacizumab (2) · Sorafenib (1) · Paclitaxel (1) · Pemetrexed (1) · Cobimetinib (1) · Vemurafenib (1)
Studies
Open first, then newest update. How each study uses onartuzumab is read from its arms, and is right about nine times in ten.
Testing it · 15
- An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored StudyCompletedPhase 3Hoffmann-La RocheNCT02488330Written as Onartuzumab
- A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent GlioblastomaCompletedPhase 2Hoffmann-La RocheNCT01632228Written as Onartuzumab
- FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal CancerCompletedPhase 2Genentech, Inc.NCT01418222Written as onartuzumab [MetMAb]
- A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)CompletedPhase 2Genentech, Inc.NCT00854308Written as MetMAb
- The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02031731Written as 4 mg/kg Onartuzumab (MetMAb)
- A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT02031744Written as Onartuzumab [MetMAb]
- Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerCompletedPhase 2Genentech, Inc.NCT01186991Written as Onartuzumab
- A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)CompletedPhase 3Genentech, Inc.NCT01456325Written as Onartuzumab (MetMab)
- A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal CancerCompletedPhase 3Hoffmann-La RocheNCT01662869Written as Onartuzumab
- A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) MutationCompletedPhase 3Hoffmann-La RocheNCT01887886Written as onartuzumab
- A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 1Hoffmann-La RocheNCT01897038Written as Onartuzumab
- Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer PatientsWithdrawnPhase 1Hoffmann-La RocheNCT01974258Written as Onartuzumab
- A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung CancerCompletedPhase 2Genentech, Inc.NCT01496742Written as RO5490258
- A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung CancerCompletedPhase 2Genentech, Inc.NCT01519804Written as onartuzumab
- A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal CancerCompletedPhase 2Hoffmann-La RocheNCT01590719Written as Onartuzumab (MetMAb)
Given in every arm · 2 — onartuzumab is usual care beside what is tested
- A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Genentech, Inc.NCT01068977Written as MetMAb
- Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)WithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT02044601Written as Onartuzumab
Codes
What other systems call onartuzumab · ClinicalTrials.gg INT006365
- MeSH (NLM) C584058onartuzumabConfirmed NLM, Wikidata
- UNII (FDA) MS1J9720WCONARTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7091711OnartuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82348OnartuzumabOne source FDA
- DrugBank DB11746One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584058 | onartuzumab | Confirmed NLM, Wikidata |
| UNII (FDA) | MS1J9720WC | ONARTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7091711 | Onartuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82348 | Onartuzumab | One source FDA |
| DrugBank | DB11746 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.